AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB: AVAI), IQVIA Holdings Inc. (NYSE: IQV), SoundHound AI, Inc. (NASDAQ: SOUN), RadNet, Inc. (NASDAQ: RDNT), and The Cigna Group (NYSE: CI).

According to McKinsey's Global Institute, generative AI isn't just a buzzword — it could deliver between $60 and $110 billion in annual value just within pharma and medical products. Meanwhile, Statista now expects the broader AI healthcare market to explode from $11 billion today to a staggering $188 billion by 2030, reflecting a major shift in how technology is expected to transform patient care, diagnostics, and operational efficiency.

For example, screenings for diabetic retinopathy are now live across Costa Rica, Nicaragua, and Panama after Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech began rolling out free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The quick, non-invasive test looks for early retinal changes that often appear before symptoms, then delivers secure results in minutes. By placing the service in retail pharmacies—and preparing a parallel launch in Mexico—the partners are moving care closer to patients while collecting real-world evidence that can guide wider commercialization.

"As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient."